European Commission Approves Janssen’s Multiple Myeloma Treatment Darzalex (Daratumumab)
The European Commission (EC) has granted provisional approval…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
New Clinical Trial for Multiple Myeloma Patients to Evaluate Safety and Efficacy of SurVaxM Vaccine
An immune-based vaccine created by researchers at Buffalo, New…
Iceni Planning a Phase 2 Study of Cilengitide in Multiple Myeloma Patients
Iceni Pharmaceuticals, formerly known as Big DNA Ltd.,…
Myeloma Foundation Claims Controversial Drug Report Could Limit Access to Best Treatments
The International Myeloma Foundation (IMF), the largest organization…
Data on Combo Therapy for Multiple Myeloma to Be Presented by PharmaMar at ASCO Meeting
Positive data for the Phase 1 trial of…
Amgen to Present New Data on Kyprolis, a Multiple Myeloma Treatment, at EHA 2016
Amgen announced it will present new data on its cancer…
